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ABSTRACT
The aim of this study was to investigate the clinical and epidemiological characteristics of five
consecutive cases of infection with vancomycin-resistant enterococci (VRE) and the prevalence of
faecal carriage of VRE among patients admitted to a 700-bed university hospital where no VRE had
been isolated previously. In a 2-month period, five consecutive patients infected with VRE were
detected. Three VanB+ Enterococcus faecium isolates were obtained from three patients, while two
VanA+ E. faecium isolates, one VanA+ Enterococcus faecalis isolate and one VanC1+ Enterococcus
gallinarum isolate were obtained from the other two patients. Of 218 faecal specimens from all
hospital wards, 41 (18.8%) were found to contain VRE. Forty-two isolates of VRE were obtained,
comprising one (2%) E. faecalis, 11 (27%) E. faecium, 24 (57%) E. gallinarum and six (14%) Enterococcus
casseliflavus ⁄ flavescens. Four isolates carried the vanA gene, eight carried vanB, 24 carried vanC1, and
six carried vanC2 ⁄C3. Use of glycopeptides, the presence of central venous catheters and renal
dialysis all correlated with VRE colonisation. The prevalence rates were among the highest reported
in the literature.
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INTRODUCTION
Enterococci are normal inhabitants of the human
and animal bowel that have attracted much
interest during recent years as a leading cause of
nosocomial infections [1,2] and because of their
increasing resistance to a variety of antimicrobial
agents, including glycopeptides [3,4]. Vancomy-
cin-resistant enterococci (VRE), first reported in
the UK in 1988 [5,6], are now distributed
worldwide [7–11]. Although nosocomial trans-
mission of VRE from patient to patient has been
emphasised in the USA [12], a growing number
of reports from Europe suggest that VRE colo-
nisation occurs frequently in the community
[13,14]. In the USA, nosocomial spread of VRE is
associated primarily with the increasing use of
vancomycin, while community-acquired coloni-
sation with VRE in Europe may be related to the
use of glycopeptides, particularly avoparcin, for
growth promotion in livestock [11,15,16].
Vancomycin resistance in enterococci is variable
on many levels, because multiple resistance genes
are involved. Five different well-described types
of vancomycin resistance are known, each associ-
ated with a different ligase gene (vanA, vanB,
vanC1, vanC2 ⁄C3, vanD and vanE). VanC-type
resistance (low-level resistance to vancomycin,
but susceptibility to teicoplanin) is an inherent,
non-transferable property of Enterococcus gallina-
rum and Enterococcus casseliflavus ⁄ flavescens that is
related to the presence of the species-specific
genes vanC1 and vanC2 ⁄C3, respectively [17,18],
while all other types (VanA, VanB, VanD and
VanE) are acquired, transferable and inducible
properties that are encoded by gene clusters
[19,20]. VanA-type strains are typically highly
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resistant to vancomycin and teicoplanin, while
VanB types, and the newly described VanD and
VanE types, are associated with moderate-to-high
levels of vancomycin resistance, but are suscept-
ible to teicoplanin [21,22]. The VanA and VanB
types are the most common [20], accounting for
c. 60% and 40%, respectively, of isolates of VRE in
the USA [23]. Inducible genes, encoding these
phenotypes, alter cell wall synthesis and render
strains resistant to glycopeptides [20].
Although vancomycin-resistant clinical isolates
of Enterococcus faecium with the VanA or VanB
phenotype have been reported previously in
Greek tertiary hospitals [24,25], no infections with
VRE had been reported in our hospital and
nothing was known of the epidemiology of VRE
inside or outside of the hospital’s wards. In a
2-month period (December 2000 to January 2001),
five infections with VRE were detected. The
preventive measures recommended by the Cen-
ters for Disease Control [26,27] were immediately
applied to avoid intra-hospital dissemination. In
addition, a point-prevalence survey was per-
formed to investigate the prevalence of faecal
carriage of VRE among patients admitted to the
hospital.
MATERIALS AND METHODS
Patients
The clinical and epidemiological features of the five patients
infected with VRE were recorded. The prevalence study on
intestinal colonisation with VRE among patients in the entire
hospital was performed on 1 February 2001. All patients in
high-risk departments (defined as areas where critically ill
patients were treated and invasive procedures were per-
formed) were sampled, including four patients in the general
intensive care unit (ICU), seven in the cardiology ICU, 72 in the
renal unit, and 15 in the neonatal unit. In addition, through a
systematic random sampling process, 120 (25.8%) of the 465
patients treated in other wards of the hospital (non-high-risk
departments) were also tested. Every case of faecal carriage
was discussed with the patient’s physician, in order to exclude
true enterococcal infection.
Culture
One faecal sample or rectal swab was obtained from every
patient participating in the study. The samples were inocula-
ted into Enterococci broth (Chromocult; Merck, Darmstadt,
Germany) supplemented with vancomycin (Lilly, Indianapo-
lis, IN, USA) 6 mg ⁄L. After incubation at 37C for 24 h, all
broth cultures were subcultured onto bile-esculin azide agar
plates (Diagnostics Pasteur, Marnes-la-Coquette, France) sup-
plemented with vancomycin 6 mg ⁄L, and were incubated at
37C for 24–72 h [14,28,29].
Identification and antimicrobial susceptibility tests
Colonies growing on agar with a dark brown halo and
resembling enterococci morphologically were identified ini-
tially by Gram’s stain, catalase activity and the presence of the
Lancefield group D antigen. Resistance to vancomycin and
teicoplanin was tested by disk diffusion and Etest (AB Biodisk,
Solna, Sweden) [30,31]. Identification to the species level was
done with the API 20 STREP system (bioMe´rieux, Marcy
l’Etoile, France), motility tests and pigment production tests
[32], and was confirmed by multiplex PCR. Susceptibility to
ampicillin, penicillin, streptomycin (high-level resistance),
gentamicin (high-level resistance), tetracycline, rifampicin,
chloramphenicol, erythromycin, norfloxacin and imipenem
was tested by disk diffusion, with MICs determined by Etest
and ⁄or agar dilution [30,33], with Enterococcus faecalis ATCC
29212, Staphylococcus aureus ATCC 29213 and E. faecium
BM4147 (VanA+) as reference strains.
Multiplex PCR and sequencing
Molecular characterisation was done with the multiplex PCR
assay described by Kariyama et al. [34], with the following
modifications. Total DNA from each isolate was extracted by
proteinase K and phenol–chloroform treatment. PCR primers
for vanC1, vanC2 ⁄C3, ddl and rrs were as described previously.
VanA amplification was done with primers vanA (5¢-AAAG-
GAGACAGGAGCATG) and vanArev (5¢-TTACATACGTCGG
GTTTCC) to yield a 1727-bp fragment, while vanB was
amplified with primers vanB (5¢-ATGAATAGAATAAAAGT
CGC) and vanBrev (5¢-TTATCACCTCTTTAACGCC) to yield a
1032-bp fragment. Primers were used at the following concen-
trations: vanC1 0.15 lM; van C2/C3 0.15 lM; ddlE. faecalis, 0.1 lM;
ddlE. faecium, 0.025 lM; rrs, 0.025 lM; vanA, 0.2 lM; and vanB,
0.15 lM; . The PCR annealing temperature was 54C, and the
extension time was 180 s. PCR product identity was confirmed
by automated sequencing with a Thermo Sequenase Kit
(Amersham Bioscience, Piscataway, NJ, USA) and alignment
of the deduced sequences with the use of BLAST software
(http://www.ncbi.nlm.nih.gov).
Epidemiological investigation
Risk factors predisposing to faecal colonisation with VRE were
investigated with the Epi-Info 6.0b database program (Centers
for Disease Control, Atlanta, GA, USA), in order to analyse
demographic characteristics and clinical data for all patients
participating in the study. These data included sex, age, days
of hospitalisation, surgical interventions, antibiotic treatment
and invasive procedures (central venous catheterisation, intu-
bation, urine catheterisation, renal dialysis, gastroscopy or
colonoscopy). Data on vancomycin consumption were
obtained from the pharmacy department.
RESULTS
Patients
Table 1 lists data for the five patients infected with
VRE, including demographic characteristics, the
site of infection, the outcome, the type and
distribution of vancomycin resistance phenotypes,
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and resistance to aminoglycosides. Three VanB+
E. faecium isolates were obtained from three
different patients infected with VRE, with each
isolate having a different antibiotic susceptibility
profile. Two VanA+ E. faecium isolates with
different antibiotic susceptibility profiles were
obtained from the remaining two patients,
together with a VanC1+ E. gallinarum isolate
from one patient, and a VanA+ E. faecalis isolate
from the other. Three patients died following
infection with VRE, while the other two were
eventually discharged from the hospital. No
other case of infection with VRE was detected
in the hospital during the year 2001.
Prevalence of colonisation with VRE
In total, 218 samples were tested, yielding
42 isolates of VRE from 41 (18.8%) patients (one
patient yielded two different isolates). VRE were
isolated from 16 (13.3%) of 120 patients in non-
high-risk departments, and from 25 (25.5%) of
98 patients in high-risk departments, with the
highest prevalence (50%) being in the ICU. A
high prevalence (29.2%) was also found in the
renal unit. There were no significant differences in
the prevalence rates of VRE between medical,
surgical and paediatric wards. The species isola-
ted were one (2%) E. faecalis, 11 (27%) E. faecium,
24 (57%) E. gallinarum, and six (14%) E. casse-
liflavus ⁄ flavescens.
Isolates with the VanA resistance type were
detected only in the high-risk ICU and renal unit
(four of 98 specimens). Three VanB-type isolates
were obtained from the 98 patients in high-risk
departments, and four from 120 patients tested
in the other wards of the hospital. One patient in
the cardiology ICU carried two strains (E. faecium
and E. faecalis) with the VanB type of resistance.
A second carrier of a VanB+ E. faecium isolate
was identified in the adult ICU, and a third in
the renal unit. The remaining four VanB+ E.
faecium isolates were identified in the haematol-
ogy (one isolate), cardiology (two isolates) and
orthopaedic (one isolate) wards. Strains with
intrinsic vancomycin resistance (E. gallinarum
and E. casseliflavus ⁄ flavescens) were found in all
the wards of the hospital, with VanC-type
isolates being obtained from 18 (18.3%) of 98
specimens in the high-risk departments, and
from 12 (10%) of 120 specimens in the other
wards of the hospital.
Identification of isolates and antibiotic
susceptibilities
All isolates (seven from the infected patients and
42 from the faecal carriers) were identified to the
genus level by conventional methods. Based on
motility, pigment production and the API 20
Strep system, all but two isolates were success-
fully identified to the species level. The remaining
two strains were non-motile and non-pigmented,
but phenotypically resembled E. gallinarum. Their
identification as E. gallinarum was confirmed, as
was that of the other isolates, by the multiplex
PCRmethod. MICs for the E. faecium and E. faecalis
isolates are presented in Table 2. All E. gallinarum
and E. casseliflavus ⁄ flavescens isolates were sus-
ceptible to ampicillin, penicillin and imipenem,
and had low-level resistance to gentamicin and
(all except one) streptomycin.
Multiplex PCR analysis
PCR products of the expected sizes of 320, 484,
658, 822, 941, 1032 and 1727 bp (corresponding to
rrs, vanC2 ⁄C3, ddlE. faecium, vanC1, ddlE. faecalis, vanB,
and vanA, respectively) were obtained, as shown
in Fig. 1. Sequencing of the PCR products
Table 1. Clinical and bacteriological characteristics of five patients infected with vancomycin-resistant enterococci
Patient Sex
Age
(years) Unit
Date of
isolation
(day ⁄month ⁄ year)
Site of
isolation Species
VRE
type STR GM Outcome
1 F 78 Nephrology 18 ⁄ 12 ⁄ 2000 Pleural fluid E. faecium VanB HLR HLR Died
2 M 36 Orthopaedic 02 ⁄ 01 ⁄ 2001 Soft tissue E. faecium VanB HLR LLR Discharged
3 F 70 ICU 05 ⁄ 01 ⁄ 2001 Peritoneal
fluid
E. faecium VanA HLR HLR Died
4 M 52 Internal
medicine
08 ⁄ 01 ⁄ 2001 Soft tissue E. faecium
E. faecalis
VanA
VanA
HLR
HLR
LLR
HLR
Discharged
5 M 70 ICU 19 ⁄ 01 ⁄ 2001 Peritoneal
fluid
E. faecium VanB LLR LLR Died
M, male; F, female; ICU, intensive care unit; STR, streptomycin; GM, gentamicin; HLR, high-level resistance; LLR, low-level resistance.
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confirmed the specificity of the vanA and vanB
primers in the E. faecium and E. faecalis isolates.
The results of PCR analysis were in agreement
with the identification and resistance phenotype
for all but two isolates. For these non-motile
strains, identification by conventional methods
was unclear, but the PCR assay yielded products
corresponding to E. gallinarum.
Risk factors for colonisation with VRE
Renal dialysis and central venous catheterisation
were associated with an increased risk of intesti-
nal colonisation with VRE (p 0.004 and p 0.003,
respectively). The use of antibiotic therapy in
general was not recognised as a risk factor, but
glycopeptide use was associated with colonisa-
tion with VRE (Table 3) (p 0.041). Following
logistic regression analysis, only previous use of
vancomycin was found to be significantly and
independently associated with intestinal coloni-
sation with VRE (odds ratio 3.2; p 0.0374; 95%
confidence interval 0.07–9.56). Data from the
pharmacy department showed that use of vanco-
mycin in the ICU increased from 137 defined
daily doses (DDD) ⁄ 1000 patient-days in 1998, to
143 DDD ⁄ 1000 patient-days in 1999, to 271
DDD ⁄ 1000 patient-days in 2000. Similar increases
were recorded in other departments (haematol-
ogy, orthopaedics, etc.).
DISCUSSION
Vancomycin resistance does not emerge de novo in
susceptible enterococci exposed to this agent.
Therefore, the first step towards infection with
VRE must be exposure to a resistant enterococcal
strain. There have been several epidemiological
studies on the ways in which patients come into
contact with VRE. It is believed that resistant
strains are spread in hospitals primarily by cross-
contamination. The results of recent molecular
epidemiological studies have refined our under-
standing of this phenomenon. If VRE are not
controlled as soon as possible, sporadic cases may
evolve into a monoclonal outbreak, which may
Table 2. Antibiotic susceptibilities of Enterococcus faecium and Enterococcus faecalis isolates from patients and faecal carriers
Strain Ward
Site of
isolation Species
MIC (mg ⁄L)
Van
genotypeAMP PEN STR GM TE RA C E NOR IMP VA TEC
28223 Nephrology Pleural fluid E. faecium 128 512 > 4096 1024 0.5 > 128 2 > 2048 > 256 512 128 0.125 vanB
93 Orthopaedic Soft tissue E. faecium 128 512 2048 16 0.25 > 128 2 2 > 256 256 256 0.125 vanB
438 ICU Peritoneal
fluid
E. faecium 128 512 2048 1024 < 0.125 16 8 > 2048 > 256 512 512 128 vanA
610 Internal
medicine
Soft tissue E. faecium 128 512 > 4096 16 0.25 0.016 2 > 512 128 512 512 128 vanA
1909 Internal
medicine
Soft tissue E. faecalis 1 8 > 4096 > 2048 64 1 8 > 2048 128 16 512 128 vanA
1646 ICU Peritoneal
fluid
E. faecium 64 128 32 4 16 8 32 > 2048 64 256 64 0.25 vanB
18 Cardiology Faeces E. faecium 64 128 32 < 4 32 8 32 > 2048 256 256 64 0.5 vanB
19 Cardiology Faeces E. faecium 64 64 2048 16 32 8 32 > 2048 32 256 128 0.5 vanB
21 ICU Faeces E. faecium 64 256 > 4096 1024 256 64 64 > 2048 2 256 512 128 vanA
22a CICU Faeces E. faecium 64 128 32 4 32 8 32 > 2048 64 256 128 0.5 vanB
22b CICU Faeces E. faecalis 1 8 > 4096 > 2048 32 0.5 16 > 2048 256 16 64 0.5 vanB
23 ICU Faeces E. faecium 64 128 32 8 32 8 32 > 2048 128 1024 128 1 vanB
32 Orthopaedic Faeces E. faecium 128 1024 > 4096 16 256 8 4 > 2048 8 256 256 0.5 vanB
34 Haematology Faeces E. faecium 128 > 1024 4096 512 0.5 1024 4 > 2048 1024 512 512 0.5 vanB
38 Renal Faeces E. faecium 64 512 2048 2048 0.5 1024 2 > 2048 512 1024 512 0.25 vanB
39 Renal Faeces E. faecium 128 512 8 64 128 0.03 8 > 2048 0.5 32 1024 128 vanA
42 Renal Faeces E. faecium 0.25 4 64 8 128 < 0.03 64 > 2048 2 4 1024 128 vanA
47 Renal Faeces E. faecium 128 > 1024 > 4096 1024 256 16 32 > 2048 1 128 512 128 vanA
M, male; F, female; ICU, intensive care unit; CICU, cardiology ICU; AMP, ampicillin; PEN, penicillin; STR, streptomycin; GM, gentamicin; TE, tetracycline; RA, rifampicin;
C, chloramphenicol; E, erythromycin; NOR, norfloxacin; IMP, imipenem; VA, vancomycin; TEC, teicoplanin.
vanA 1727bp
vanB 1032bp
vanC 1822bp
vanC2/C3 484bp
rrs 320bp
E.faecium 658bp
vanA 1727bp
vanB 1032bp
vanC 1822bp
vanC2/C3 484bp
rrs 320bp
E.faecalis 941bp
1 2 3 4 M M 5 6 7 8
Fig. 1. Agarose gel electrophoresis of amplified vanA,
vanB, vanC1, vanC2 ⁄C3, E. faecalis-specific, E. faecium-
specific and rrs genes by the multiplex PCR assay contain-
ing seven primer sets. Lanes: 1, E. faecalis vanB; 2 and 5,
E. gallinarum vanC1; 3, E. faecalis vanA; 4 and 6, E. casse-
liflavus ⁄ flavescens; 7, E. faecium vanB; 8, E. faecium vanA;
M, 1-kb DNA ladder.
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then evolve to polyclonal endemicity [35]. Thus,
in hospitals where outbreaks of VRE are detected
at an early stage, they have been caused by a
single strain [24,36–38], whereas multiple clones
are encountered when VRE have been present in a
hospital for a long time [24,39].
E. faecium was the clinical isolate detected most
frequently in our patients, with only a single
vancomycin-resistant strain of E. faecalis being
isolated. In addition, two different strains (one
E. gallinarum and one E. faecium) were derived
from the same patient during this period. The
isolates from infected patients demonstrated vari-
ability in their vancomycin resistance phenotypes,
with VanB being the predominant phenotype of
the E. faecium clinical isolates. However, the VanA
phenotype was detected in E. faecium and E. fae-
calis, and the VanC phenotype was detected in
E. gallinarum, indicating wide institutional spread
of vancomycin-resistant enterococci. These data
suggest that the hospital had been colonised
previously with undetected strains of VRE.
Specific surveillance of patients to detect gas-
trointestinal colonisation has often proved useful
during outbreaks and should be considered an
essential component of successful control pro-
grammes for VRE [15,27,36,37]. The present study
detected faecal carriers in most of the wards with
patients infected with VRE, but not among
patients in the nephrology and internal medicine
wards. However, these patients were previously
cared for in departments with high prevalence
rates. Faecal carriers of VanA+ or VanB+ strains
were also found in departments where no infec-
tion with VRE had been detected, indicating
further dissemination within the hospital. In
Europe, the reported prevalences of faecal colo-
nisation with VRE among hospitalised patients
are 2% in The Netherlands [40], 2.7% in the UK
[41], 4.9% in the ICUs of French general hospitals
[42], and 3.5% in Belgium [7]. The prevalence rate
(18.8%) found in the present study was higher
than those reported elsewhere in Europe, and
seems closer to the levels reported from Texas
(16%) and New York (28%) [37,43].
The distribution pattern of carriage of VRE
observed in the USA showed a predominance of
E. faecium isolates [44,45], but the proportions of
E. gallinarum and E. casseliflavus isolates were very
low, ranging from 0.5% to 1% [44], while 59.5%
of the isolates in the present study were E. gallin-
arum and 14.2% were E. casseliflavus ⁄ flavescens.
The results of a few European studies have shown
variable isolation rates of these species, ranging
from 5.9% to 13.6% [7,40,42]. Since E. gallinarum
and E. casseliflavus are recovered rarely from
clinical specimens, these species are not always
taken into account, because their resistance to
glycopeptides is intrinsic and their pathogenicity
is low.
Inter-hospital spread of clonal strains, suggest-
ing patient-to-patient transmission, is the factor
responsible for most outbreaks of VRE in the USA
[39,44,45]. VRE (mainly with the vanA genotype)
are isolated frequently from non-hospitalised
patients, animals and environmental sources in
Europe [7,16,46,47]. Passage of these bacteria from
animals through the food chain has linked this
community source of VRE to the extensive use of
avoparcin, a glycopeptide used as an animal food
supplement [11,16,48]. Furthermore, macrolides
(e.g., tylosin), which are also used for growth
promotion of animals, may lead to co-selection of
enterococci resistant to macrolides and glycopep-
tides [49,50]. The linkage of erythromycin and
vancomycin resistance genes in Greek strains of
E. faecium has already been described by Maniatis
et al. [25]. In the present study, all isolates were
resistant to erythromycin, with the exception of
one E. faecium isolate, but the use of macrolides in
humans was not detected as a risk factor, as none
of the patients infected with or carrying VRE had
a history of previous exposure to macrolides.
The present study identified host risk factors
for colonisation with VRE as use of glycopeptides,
Table 3. Univariate risk factor analysis for intestinal col-
onisation with vancomycin-resistant enterococci (VRE)
Variable
No (%) of
VRE carriers
(n = 41)
No (%) of
negative controls
(n = 177) p value
Male 20 (48.8) 104 (58.8) 0.32
Mean age (years) 57.1 ± 17.74 53.4 ± 23.64 0.34
Mean days of hospitalisation 7.6 ± 15.22 10 ± 20.07 0.46
Previous antibiotic therapy 14 (34.1) 76 (42.9) 0.393
Use of penicillins 6 (14.6) 33 (18.1) 0.767
Use of cephalosporins 8 (19.5) 43 (24.3) 0.655
Use of aminoglycosides 3 (7.3) 16 (9) 0.964
Use of quinolones 3 (7.3) 12 (6.8) 0.826
Use of anti-anaerobe antibiotics 4 (9.8) 19 (9.6) 0.79
Use of glycopeptides 6 (14.6) 9 (5.1) 0.041
Recent surgery 6 (14.6) 24 (13.6) 0.943
Central venous catheter 28 (68.3) 73 (41.2) 0.003
Tracheostomy 2 (4.9) 4 (2.3) 0.69
Intubation 4 (9.6) 9 (5.1) 0.44
Indwelling urine catheter 7 (17.1) 27 (15.3) 0.96
Renal dialysis 22 (53.7) 51 (28.8) 0.004
Gastroscopy 2 (4.9) 2 (1.1) 0.33
Colonoscopy 1 (2.4) 4 (2.3) 0.61
p values were calculated with the chi-square test with Yates’ correction.
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presence of a central venous catheter, and renal
dialysis, associated indirectly with the patient’s
underlying illness. It was also confirmed that use
of vancomycin significantly and independently
influenced (p 0.041) selection for VRE in the
intestinal flora, but that use of cephalosporins or
any other antibiotic did not. Vancomycin use
seems to play a crucial role in increased faecal
carriage and, subsequently, development of
infection. This may also be a possible explanation
for the higher frequency and the wider distribu-
tion of the VanB resistance type. High-level
vigilance with continuous surveillance and labor-
atory-oriented infection control measures are
necessary to improve the current situation.
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